Disclosed is an anti-hPG monoclonal antibody that specifically binds a C-terminal region of human progastrin (hPG), wherein the anti-hPG monoclonal antibody yields a statistically significant reduction in the number of live colorectal cancer cell lines after in vitro treatment of a test sample as compared to a control sample treated with a non-specific monoclonal antibody. Also disclosed is the use of the antibody in treating colorectal cancer.